Jump Financial LLC Takes $313,000 Position in Organogenesis Holdings Inc. (NASDAQ:ORGO)

Jump Financial LLC acquired a new stake in shares of Organogenesis Holdings Inc. (NASDAQ:ORGO - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 97,950 shares of the company's stock, valued at approximately $313,000. Jump Financial LLC owned approximately 0.08% of Organogenesis at the end of the most recent quarter.

Other large investors have also bought and sold shares of the company. Virtu Financial LLC bought a new stake in Organogenesis during the 4th quarter worth approximately $38,000. Palumbo Wealth Management LLC bought a new stake in shares of Organogenesis in the 4th quarter valued at about $65,000. Mariner LLC purchased a new position in Organogenesis during the fourth quarter valued at approximately $123,000. Wells Fargo & Company MN boosted its stake in Organogenesis by 29.6% in the fourth quarter. Wells Fargo & Company MN now owns 41,471 shares of the company's stock valued at $133,000 after acquiring an additional 9,464 shares in the last quarter. Finally, SG Americas Securities LLC lifted its stake in shares of Organogenesis by 66.4% during the fourth quarter. SG Americas Securities LLC now owns 41,746 shares of the company's stock worth $134,000 after buying an additional 16,660 shares during the period. 49.57% of the stock is owned by hedge funds and other institutional investors.

Organogenesis Stock Performance

Shares of ORGO stock traded up $0.21 during midday trading on Tuesday, hitting $4.88. The company had a trading volume of 1,879,310 shares, compared to its average volume of 1,131,399. The company has a debt-to-equity ratio of 0.21, a current ratio of 3.09 and a quick ratio of 2.74. The company's 50 day simple moving average is $4.49 and its 200 day simple moving average is $3.80. Organogenesis Holdings Inc. has a 52-week low of $2.21 and a 52-week high of $6.71. The stock has a market cap of $618.92 million, a price-to-earnings ratio of -81.33 and a beta of 1.79.

Insider Buying and Selling

In other Organogenesis news, Director Michael Joseph Driscoll sold 25,000 shares of the firm's stock in a transaction on Tuesday, March 4th. The shares were sold at an average price of $5.10, for a total transaction of $127,500.00. Following the completion of the transaction, the director now directly owns 166,879 shares of the company's stock, valued at $851,082.90. This trade represents a 13.03 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 36.90% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Separately, Morgan Stanley lifted their price objective on shares of Organogenesis from $4.00 to $6.00 and gave the company an "equal weight" rating in a report on Wednesday, March 5th.

About Organogenesis

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.